Sinocompound announces new licensing agreement with Dalhousie University

Pharmaceutical

Sinocompound Catalysts Co., Ltd, has announced a new licensing agreement for a range of novel non-platinum group metal (non-PGM) catalysts from Dalhousie University, Canada. These advanced non-PGM catalysts contain a 'DalPhos' phosphine-based ancillary ligand, allowing access to a range of challenging C-N/C-O cross-couplings. DalPhos ligands and their preformed Ni catalysts will be scaled-up, manufactured and supplied by Sinocompound, further building out the company’s portfolio of non-PGM catalysts alongside their extensive range of PGM catalysts and associated ligands. The DalPhos ligands were developed by Prof. Mark Stradiotto and his research team at the Department of Chemistry, Dalhousie University.

Sinocompound has an extensive portfolio of catalysts and the ability to scale up production rapidly as required. Their established team of metal catalyst and ligand experts work in partnership with customers to help them find solutions to challenging chemistry and speed-up their route to market.

“Sinocompound announces new licensing agreement with Dalhousie University.“

Research efforts in the Stradiotto group are directed toward developing new classes of ancillary ligands/transition metal complexes that exhibit interesting and unusual reactivity patterns, with the goal of incorporating such reactivity into synthetically useful catalytic substrate transformations that can be employed by end-users.

Dr Carin Seechurn, associate director – technology solutions, Sinocompound, commented, “The licensing of these ligands from Dalhousie University helps to further strengthen the range of non-PGM catalysts offered by Sinocompound and will be hugely beneficial when working with customers to help develop their non-PGM-based processes. In today’s pharmaceutical industry, PGM chemistries provide a well-established solution, however, there can be a number of advantages to using non-PGM catalysts. These include the obvious potential cost savings over PGM catalysts, and in some cases, non-PGMs may offer solutions that can’t be achieved with PGM catalysts, such as a carbon-nitrogen bond formation reaction between a fluorinated amine and inexpensive aryl chlorides or phenol derivatives."

See all the latest jobs in Pharmaceutical
Return to news